ADTEC INSERTO MICROPINZA ATR.5/310MM

Informazioni principali

  • Nome commerciale:
  • ADTEC INSERTO MICROPINZA ATR.5/310MM
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • ADTEC INSERTO MICROPINZA ATR.5/310MM
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • PINZE PLURIUSO PER CHIRURGIA MINI-INVASIVA

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • S
  • Data dell'autorizzazione:
  • 20-11-2009
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

16-1-2019

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

FDA approved the first generic version of Sabril for treating complex partial seizures, as an adjunctive therapy in certain patients.

FDA - U.S. Food and Drug Administration

21-12-2018

FDA approves first treatment for rare blood disease

FDA approves first treatment for rare blood disease

The FDA approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.

FDA - U.S. Food and Drug Administration

9-12-2018

TachoSil

TachoSil

Product approval information is indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.

FDA - U.S. Food and Drug Administration

4-12-2018


European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, European Medicines Agency via Adobe Connect, from 22/10/2018 to 22/10/2018

European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, European Medicines Agency via Adobe Connect, from 22/10/2018 to 22/10/2018

European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, European Medicines Agency via Adobe Connect, from 22/10/2018 to 22/10/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, decision type: , therapeutic area: , PIP number: P/0330/2018

Opinion/decision on a Paediatric investigation plan (PIP): 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, decision type: , therapeutic area: , PIP number: P/0330/2018

Opinion/decision on a Paediatric investigation plan (PIP): 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, decision type: , therapeutic area: , PIP number: P/0330/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Telisotuzumab vedotin, decision type: , therapeutic area: , PIP number: P/0331/2018

Opinion/decision on a Paediatric investigation plan (PIP): Telisotuzumab vedotin, decision type: , therapeutic area: , PIP number: P/0331/2018

Opinion/decision on a Paediatric investigation plan (PIP): Telisotuzumab vedotin, decision type: , therapeutic area: , PIP number: P/0331/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Irbesartan / amlodipine, decision type: , therapeutic area: , PIP number: P/0245/2018

Opinion/decision on a Paediatric investigation plan (PIP): Irbesartan / amlodipine, decision type: , therapeutic area: , PIP number: P/0245/2018

Opinion/decision on a Paediatric investigation plan (PIP): Irbesartan / amlodipine, decision type: , therapeutic area: , PIP number: P/0245/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Tepotinib, decision type: , therapeutic area: , PIP number: P/0279/2018

Opinion/decision on a Paediatric investigation plan (PIP): Tepotinib, decision type: , therapeutic area: , PIP number: P/0279/2018

Opinion/decision on a Paediatric investigation plan (PIP): Tepotinib, decision type: , therapeutic area: , PIP number: P/0279/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Ianalumab, decision type: , therapeutic area: , PIP number: P/0332/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ianalumab, decision type: , therapeutic area: , PIP number: P/0332/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ianalumab, decision type: , therapeutic area: , PIP number: P/0332/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, decision type: , therapeutic area: , PIP number: P/0232/2018

Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, decision type: , therapeutic area: , PIP number: P/0232/2018

Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, decision type: , therapeutic area: , PIP number: P/0232/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Ibalizumab, decision type: , therapeutic area: , PIP number: P/0271/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibalizumab, decision type: , therapeutic area: , PIP number: P/0271/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibalizumab, decision type: , therapeutic area: , PIP number: P/0271/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys(γ-Glu-palmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly-OH (MEDI0382), decision type: , therapeutic area: , PIP nu

Opinion/decision on a Paediatric investigation plan (PIP): His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys(γ-Glu-palmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly-OH (MEDI0382), decision type: , therapeutic area: , PIP nu

Opinion/decision on a Paediatric investigation plan (PIP): His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys(γ-Glu-palmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly-OH (MEDI0382), decision type: , therapeutic area: , PIP number: P/0235/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Recombinant human acid ceramidase (RVT-801), decision type: , therapeutic area: , PIP number: P/0319/2018

Opinion/decision on a Paediatric investigation plan (PIP): Recombinant human acid ceramidase (RVT-801), decision type: , therapeutic area: , PIP number: P/0319/2018

Opinion/decision on a Paediatric investigation plan (PIP): Recombinant human acid ceramidase (RVT-801), decision type: , therapeutic area: , PIP number: P/0319/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Ferric pyrophosphate citrate, decision type: , therapeutic area: , PIP number: P/0263/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ferric pyrophosphate citrate, decision type: , therapeutic area: , PIP number: P/0263/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ferric pyrophosphate citrate, decision type: , therapeutic area: , PIP number: P/0263/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Ivosidenib, decision type: , therapeutic area: , PIP number: P/0280/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ivosidenib, decision type: , therapeutic area: , PIP number: P/0280/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ivosidenib, decision type: , therapeutic area: , PIP number: P/0280/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): diphtheria toxin interleukin-3 Fusion Protein, decision type: , therapeutic area: , PIP number: P/0326/2018

Opinion/decision on a Paediatric investigation plan (PIP): diphtheria toxin interleukin-3 Fusion Protein, decision type: , therapeutic area: , PIP number: P/0326/2018

Opinion/decision on a Paediatric investigation plan (PIP): diphtheria toxin interleukin-3 Fusion Protein, decision type: , therapeutic area: , PIP number: P/0326/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): interferon beta-1a, decision type: , therapeutic area: , PIP number: P/0305/2018

Opinion/decision on a Paediatric investigation plan (PIP): interferon beta-1a, decision type: , therapeutic area: , PIP number: P/0305/2018

Opinion/decision on a Paediatric investigation plan (PIP): interferon beta-1a, decision type: , therapeutic area: , PIP number: P/0305/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with aluminium phosphate [Clade C gp140], decision type: , therapeutic area: , PIP number: P/0236/2018

Opinion/decision on a Paediatric investigation plan (PIP): Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with aluminium phosphate [Clade C gp140], decision type: , therapeutic area: , PIP number: P/0236/2018

Opinion/decision on a Paediatric investigation plan (PIP): Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with aluminium phosphate [Clade C gp140], decision type: , therapeutic area: , PIP number: P/0236/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Anti-mucosal addressin cell adhesion molecule antibody (SHP647), decision type: , therapeutic area: , PIP number: P/0281/2018

Opinion/decision on a Paediatric investigation plan (PIP): Anti-mucosal addressin cell adhesion molecule antibody (SHP647), decision type: , therapeutic area: , PIP number: P/0281/2018

Opinion/decision on a Paediatric investigation plan (PIP): Anti-mucosal addressin cell adhesion molecule antibody (SHP647), decision type: , therapeutic area: , PIP number: P/0281/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Autologous cartilage derived cultured chondrocytes, decision type: , therapeutic area: , PIP number: P/0282/2018

Opinion/decision on a Paediatric investigation plan (PIP): Autologous cartilage derived cultured chondrocytes, decision type: , therapeutic area: , PIP number: P/0282/2018

Opinion/decision on a Paediatric investigation plan (PIP): Autologous cartilage derived cultured chondrocytes, decision type: , therapeutic area: , PIP number: P/0282/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Inclisiran sodium, decision type: , therapeutic area: , PIP number: P/0321/2018

Opinion/decision on a Paediatric investigation plan (PIP): Inclisiran sodium, decision type: , therapeutic area: , PIP number: P/0321/2018

Opinion/decision on a Paediatric investigation plan (PIP): Inclisiran sodium, decision type: , therapeutic area: , PIP number: P/0321/2018

Europe - EMA - European Medicines Agency

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Lynparza,Olaparib, decision type: , therapeutic area: , PIP number: P/0262/2018

Opinion/decision on a Paediatric investigation plan (PIP): Lynparza,Olaparib, decision type: , therapeutic area: , PIP number: P/0262/2018

Opinion/decision on a Paediatric investigation plan (PIP): Lynparza,Olaparib, decision type: , therapeutic area: , PIP number: P/0262/2018

Europe - EMA - European Medicines Agency

14-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, decision type: , therapeutic area: , PIP number: P/0254/2018

Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, decision type: , therapeutic area: , PIP number: P/0254/2018

Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, decision type: , therapeutic area: , PIP number: P/0254/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,baricitinib, decision type: , therapeutic area: , PIP number: P/0291/2018

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,baricitinib, decision type: , therapeutic area: , PIP number: P/0291/2018

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,baricitinib, decision type: , therapeutic area: , PIP number: P/0291/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Kevzara,sarilumab, decision type: , therapeutic area: , PIP number: P/0335/2018

Opinion/decision on a Paediatric investigation plan (PIP): Kevzara,sarilumab, decision type: , therapeutic area: , PIP number: P/0335/2018

Opinion/decision on a Paediatric investigation plan (PIP): Kevzara,sarilumab, decision type: , therapeutic area: , PIP number: P/0335/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Adcetris,Brentuximab vedotin, decision type: , therapeutic area: , PIP number: P/0327/2018

Opinion/decision on a Paediatric investigation plan (PIP): Adcetris,Brentuximab vedotin, decision type: , therapeutic area: , PIP number: P/0327/2018

Opinion/decision on a Paediatric investigation plan (PIP): Adcetris,Brentuximab vedotin, decision type: , therapeutic area: , PIP number: P/0327/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Veliparib, decision type: , therapeutic area: , PIP number: P/0256/2018

Opinion/decision on a Paediatric investigation plan (PIP): Veliparib, decision type: , therapeutic area: , PIP number: P/0256/2018

Opinion/decision on a Paediatric investigation plan (PIP): Veliparib, decision type: , therapeutic area: , PIP number: P/0256/2018

Europe - EMA - European Medicines Agency

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): navitoclax, decision type: , therapeutic area: , PIP number: P/0255/2018

Opinion/decision on a Paediatric investigation plan (PIP): navitoclax, decision type: , therapeutic area: , PIP number: P/0255/2018

Opinion/decision on a Paediatric investigation plan (PIP): navitoclax, decision type: , therapeutic area: , PIP number: P/0255/2018

Europe - EMA - European Medicines Agency

19-12-2018


Opinion/decision on a Paediatric investigation plan (PIP): Abraxane,paclitaxel, decision type: , therapeutic area: , PIP number: P/0257/2018

Opinion/decision on a Paediatric investigation plan (PIP): Abraxane,paclitaxel, decision type: , therapeutic area: , PIP number: P/0257/2018

Opinion/decision on a Paediatric investigation plan (PIP): Abraxane,paclitaxel, decision type: , therapeutic area: , PIP number: P/0257/2018

Europe - EMA - European Medicines Agency

30-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0230/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0230/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0230/2018

Europe - EMA - European Medicines Agency

30-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0231/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0231/2018

Opinion/decision on a Paediatric investigation plan (PIP): Risankizumab, decision type: , therapeutic area: , PIP number: P/0231/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Emapalumab, decision type: , therapeutic area: , PIP number: P/0152/2018

Opinion/decision on a Paediatric investigation plan (PIP): Emapalumab, decision type: , therapeutic area: , PIP number: P/0152/2018

Opinion/decision on a Paediatric investigation plan (PIP): Emapalumab, decision type: , therapeutic area: , PIP number: P/0152/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): lamivudine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0151/2018

Opinion/decision on a Paediatric investigation plan (PIP): lamivudine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0151/2018

Opinion/decision on a Paediatric investigation plan (PIP): lamivudine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0151/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, decision type: , therapeutic area: , PIP number: P/0182/2018

Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, decision type: , therapeutic area: , PIP number: P/0182/2018

Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, decision type: , therapeutic area: , PIP number: P/0182/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, decision type: , therapeutic area: , PIP number: P/0186/2018

Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, decision type: , therapeutic area: , PIP number: P/0186/2018

Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, decision type: , therapeutic area: , PIP number: P/0186/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): gabapentin, decision type: , therapeutic area: , PIP number: P/0198/2018

Opinion/decision on a Paediatric investigation plan (PIP): gabapentin, decision type: , therapeutic area: , PIP number: P/0198/2018

Opinion/decision on a Paediatric investigation plan (PIP): gabapentin, decision type: , therapeutic area: , PIP number: P/0198/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018

Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018

Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Zavicefta,Ceftazidime,avibactam, decision type: , therapeutic area: , PIP number: P/0149/2018

Opinion/decision on a Paediatric investigation plan (PIP): Zavicefta,Ceftazidime,avibactam, decision type: , therapeutic area: , PIP number: P/0149/2018

Opinion/decision on a Paediatric investigation plan (PIP): Zavicefta,Ceftazidime,avibactam, decision type: , therapeutic area: , PIP number: P/0149/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Sovaldi,Sofosbuvir, decision type: , therapeutic area: , PIP number: P/0172/2018

Opinion/decision on a Paediatric investigation plan (PIP): Sovaldi,Sofosbuvir, decision type: , therapeutic area: , PIP number: P/0172/2018

Opinion/decision on a Paediatric investigation plan (PIP): Sovaldi,Sofosbuvir, decision type: , therapeutic area: , PIP number: P/0172/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Spherox,spheroids of human autologous matrix-associated chondrocytes, decision type: , therapeutic area: , PIP number: P/0161/2018

Opinion/decision on a Paediatric investigation plan (PIP): Spherox,spheroids of human autologous matrix-associated chondrocytes, decision type: , therapeutic area: , PIP number: P/0161/2018

Opinion/decision on a Paediatric investigation plan (PIP): Spherox,spheroids of human autologous matrix-associated chondrocytes, decision type: , therapeutic area: , PIP number: P/0161/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Zinforo,Ceftaroline fosamil, decision type: , therapeutic area: , PIP number: P/0176/2018

Opinion/decision on a Paediatric investigation plan (PIP): Zinforo,Ceftaroline fosamil, decision type: , therapeutic area: , PIP number: P/0176/2018

Opinion/decision on a Paediatric investigation plan (PIP): Zinforo,Ceftaroline fosamil, decision type: , therapeutic area: , PIP number: P/0176/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/0163/2018

Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/0163/2018

Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/0163/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri,pixantrone (dimaleate), decision type: , therapeutic area: , PIP number: P/0227/2018

Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri,pixantrone (dimaleate), decision type: , therapeutic area: , PIP number: P/0227/2018

Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri,pixantrone (dimaleate), decision type: , therapeutic area: , PIP number: P/0227/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz,Tofacitinib, decision type: , therapeutic area: , PIP number: P/0203/2018

Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz,Tofacitinib, decision type: , therapeutic area: , PIP number: P/0203/2018

Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz,Tofacitinib, decision type: , therapeutic area: , PIP number: P/0203/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): trandolapril, decision type: , therapeutic area: , PIP number: P/0192/2018

Opinion/decision on a Paediatric investigation plan (PIP): trandolapril, decision type: , therapeutic area: , PIP number: P/0192/2018

Opinion/decision on a Paediatric investigation plan (PIP): trandolapril, decision type: , therapeutic area: , PIP number: P/0192/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): moxonidine, decision type: , therapeutic area: , PIP number: P/0228/2018

Opinion/decision on a Paediatric investigation plan (PIP): moxonidine, decision type: , therapeutic area: , PIP number: P/0228/2018

Opinion/decision on a Paediatric investigation plan (PIP): moxonidine, decision type: , therapeutic area: , PIP number: P/0228/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Verapamil / trandolapril, decision type: , therapeutic area: , PIP number: P/0162/2018

Opinion/decision on a Paediatric investigation plan (PIP): Verapamil / trandolapril, decision type: , therapeutic area: , PIP number: P/0162/2018

Opinion/decision on a Paediatric investigation plan (PIP): Verapamil / trandolapril, decision type: , therapeutic area: , PIP number: P/0162/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu

Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu

Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride, decision type: , therapeutic area: , PIP number: P/0134/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Andecaliximab, decision type: , therapeutic area: , PIP number: P/0169/2018

Opinion/decision on a Paediatric investigation plan (PIP): Andecaliximab, decision type: , therapeutic area: , PIP number: P/0169/2018

Opinion/decision on a Paediatric investigation plan (PIP): Andecaliximab, decision type: , therapeutic area: , PIP number: P/0169/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): eszopiclone, decision type: , therapeutic area: , PIP number: P/0133/2018

Opinion/decision on a Paediatric investigation plan (PIP): eszopiclone, decision type: , therapeutic area: , PIP number: P/0133/2018

Opinion/decision on a Paediatric investigation plan (PIP): eszopiclone, decision type: , therapeutic area: , PIP number: P/0133/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Patidegib, decision type: , therapeutic area: , PIP number: P/0218/2018

Opinion/decision on a Paediatric investigation plan (PIP): Patidegib, decision type: , therapeutic area: , PIP number: P/0218/2018

Opinion/decision on a Paediatric investigation plan (PIP): Patidegib, decision type: , therapeutic area: , PIP number: P/0218/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), decision type: , therapeutic area:

Opinion/decision on a Paediatric investigation plan (PIP): Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), decision type: , therapeutic area:

Opinion/decision on a Paediatric investigation plan (PIP): Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), decision type: , therapeutic area: , PIP number: P/0212/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Arimoclomol (citrate), decision type: , therapeutic area: , PIP number: P/0213/2018

Opinion/decision on a Paediatric investigation plan (PIP): Arimoclomol (citrate), decision type: , therapeutic area: , PIP number: P/0213/2018

Opinion/decision on a Paediatric investigation plan (PIP): Arimoclomol (citrate), decision type: , therapeutic area: , PIP number: P/0213/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): vonicog alfa, decision type: , therapeutic area: , PIP number: P/0225/2018

Opinion/decision on a Paediatric investigation plan (PIP): vonicog alfa, decision type: , therapeutic area: , PIP number: P/0225/2018

Opinion/decision on a Paediatric investigation plan (PIP): vonicog alfa, decision type: , therapeutic area: , PIP number: P/0225/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Descovy,emtricitabine,tenofovir alafenamide, decision type: , therapeutic area: , PIP number: P/0171/2018

Opinion/decision on a Paediatric investigation plan (PIP): Descovy,emtricitabine,tenofovir alafenamide, decision type: , therapeutic area: , PIP number: P/0171/2018

Opinion/decision on a Paediatric investigation plan (PIP): Descovy,emtricitabine,tenofovir alafenamide, decision type: , therapeutic area: , PIP number: P/0171/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Peanut flour, decision type: , therapeutic area: , PIP number: P/0170/2018

Opinion/decision on a Paediatric investigation plan (PIP): Peanut flour, decision type: , therapeutic area: , PIP number: P/0170/2018

Opinion/decision on a Paediatric investigation plan (PIP): Peanut flour, decision type: , therapeutic area: , PIP number: P/0170/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Epclusa,Sofosbuvir,velpatasvir, decision type: , therapeutic area: , PIP number: P/0150/2018

Opinion/decision on a Paediatric investigation plan (PIP): Epclusa,Sofosbuvir,velpatasvir, decision type: , therapeutic area: , PIP number: P/0150/2018

Opinion/decision on a Paediatric investigation plan (PIP): Epclusa,Sofosbuvir,velpatasvir, decision type: , therapeutic area: , PIP number: P/0150/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018

Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018

Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): nitrous oxide, decision type: , therapeutic area: , PIP number: P/0217/2018

Opinion/decision on a Paediatric investigation plan (PIP): nitrous oxide, decision type: , therapeutic area: , PIP number: P/0217/2018

Opinion/decision on a Paediatric investigation plan (PIP): nitrous oxide, decision type: , therapeutic area: , PIP number: P/0217/2018

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain), decision type: , therapeutic area: , PIP number: P/0219/2018

Opinion/decision on a Paediatric investigation plan (PIP): Purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain), decision type: , therapeutic area: , PIP number: P/0219/2018

Opinion/decision on a Paediatric investigation plan (PIP): Purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain), decision type: , therapeutic area: , PIP number: P/0219/2018

Europe - EMA - European Medicines Agency